Clinical trial · Interventional
Supportive Cancer Care Networkers (SCAN)
Supportive Cancer Care Networkers - a Prospective Randomized Controlled Multi-center Trial
NCT01651832CI-TRIAL-00024417SCANcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aim of the study is to increase the proportion of indicated patients with colorectal cancer undergoing adjuvant chemotherapy following surgical resection through an optimized symptom management and logistical support.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SCAN | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- usual care
- description
- routine care and case management
- type
- EXPERIMENTAL
- label
- SCAN-Intervention
- interventionNames
- Behavioral: SCAN
Primary outcomes (1)
- measure
- proportion of eligible patients undergoing adjuvant chemo therapy
- timeFrame
- 8 weeks after hospital discharge/ chrirurgical resection
Secondary outcomes (6)
- measure
- disease-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * colorectal carcinoma (ICD-10: C18, C19, C20) * indication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed * living in Saxony-Anhalt * ECOG-Performance Status \<3 * prospective further life expectancy of more than three months Exclusion Criteria: * unable to read or understand German properly * any contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).
References
Publications (1)
- DERIVEDBauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M. Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer. 2015 Dec 22;15:997. doi: 10.1186/s12885-015-2002-6. PMID 26694748